AU2003302157A1 - Vaccine for prevention and treatment of opiate addiction - Google Patents

Vaccine for prevention and treatment of opiate addiction

Info

Publication number
AU2003302157A1
AU2003302157A1 AU2003302157A AU2003302157A AU2003302157A1 AU 2003302157 A1 AU2003302157 A1 AU 2003302157A1 AU 2003302157 A AU2003302157 A AU 2003302157A AU 2003302157 A AU2003302157 A AU 2003302157A AU 2003302157 A1 AU2003302157 A1 AU 2003302157A1
Authority
AU
Australia
Prior art keywords
vaccine
prevention
treatment
opiate addiction
opiate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302157A
Inventor
Sergey Konstantinovich Sudakov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003302157A1 publication Critical patent/AU2003302157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003302157A 2003-10-03 2003-10-03 Vaccine for prevention and treatment of opiate addiction Abandoned AU2003302157A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2003/000428 WO2005032587A1 (en) 2003-10-03 2003-10-03 Vaccine for prevention and treatment of opiate addiction

Publications (1)

Publication Number Publication Date
AU2003302157A1 true AU2003302157A1 (en) 2005-04-21

Family

ID=34420867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302157A Abandoned AU2003302157A1 (en) 2003-10-03 2003-10-03 Vaccine for prevention and treatment of opiate addiction

Country Status (2)

Country Link
AU (1) AU2003302157A1 (en)
WO (1) WO2005032587A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102002049B (en) * 2010-10-12 2013-01-02 北京大学 Antigen and preparation method and application thereof
RU2707301C1 (en) * 2019-05-17 2019-11-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Low-molecular mimetic bdnf as an agent for treating opioid dependence

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363041A1 (en) * 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine

Also Published As

Publication number Publication date
WO2005032587A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
AU2003219934A1 (en) Method of treatment or prevention of obesity
AU2003231048A8 (en) Transposon system and methods of use
AU2002303283A1 (en) Methods for treating drug addiction
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
IL172004A0 (en) Polymorphic forms of ziprasidone hci and processes for their preparation
EP1789047A4 (en) Treatment of diseases using nalmefene and its analgos
AU2003287909A1 (en) Electro-therapeutic device and method of electro-therapeutic treatment
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
GB0306309D0 (en) Method of treatment
GB0324523D0 (en) Compositions and methods of treatment
GB0302572D0 (en) Method of treatment
AU2003302157A1 (en) Vaccine for prevention and treatment of opiate addiction
GB0217493D0 (en) Novel methods of treatment
AU2003280688A1 (en) Combination therapy of peptide vaccination and estramustine treatment
GB0221712D0 (en) Methods of treatment
AU2003302271A1 (en) Methods of treating and/or preventing autoimmune diseases
AU2002951913A0 (en) Method of treatment
GB0327975D0 (en) Methods of treatment
IL166083A0 (en) Methods for treatment and prevention of gastrointestinal conditions
GB0213198D0 (en) Method of treatment
AU2003901741A0 (en) Treatment for addiction
AU2003904161A0 (en) Methods of treatment
GB0207091D0 (en) Method of treatment
GB0322921D0 (en) Methods of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase